Basel, Basel, Switzerland
At Lonza Drug Product Services Basel, I lead a growing team of QC scientists performing release and stability analytics in the GMP environment. We guide our customers through the demanding early phases of future blockbusters, biosimilars and next generation therapeuticals. The DPS team enables our customers to ensure product quality and supports worldwide filing processes to make new cures available as soon as possible to their patients. In my Ph.D. I revealed interesting insights in the microbial degradation of polyisoprene latex on an enzymatic level. I focused on potential applications to employ generated oligo-isoprenoids as fine chemicals for special applications or use as a future biofuel. I consider myself a scientist with great interest in several different directions. As a trained chemist (Chemical Technician, CTA), I acquired a solid background in analytical- and synthesis- chemistry and continued my studies to gain experience in biochemistry and biotechnology. I am experienced in routine microbiological methods I designed, conducted and supervised countless experiments relying on bio-informatics, molecular biology, protein expression, purification, and the biochemical characterization of proteins. Analytical (bio-) chemistry is my favorite subject. In the pharmaceutical industry, I quickly learned a lot especially about antibodies and GMP conform quality control thereof. I enjoy writing scientifically and stilistically sound documents such as deviation, method development, product quality or qualification reports. I appreciate the opportunity to coordinate my team and enable us to go, stay and grow according to the Lonza motto. Without the DPS spirit and teamwork our research and daily work would not be possible. In my pastime I am a passionate scuba diver, and love to participate in scientific diving projects.
Established the commercial QC DP testing sector, team structure, business processes, interfaces. Successful customer and health authority audit/inspection history. Setup of regulatory documents in alignment with the customers, e.g. Commercial DP specification, method validation / transfer strategy. On time in Full DP release of first and subsequent commercial DP release and stability testing results for physico-chemical (compendial, generic, purity, identity tests) and bio-analytics (ELISA, SPR, blots). Stein Growth project: Drafted QC landscape and laboratory layouts, scope of tests offered, instrument requirements, utilities, infrastructure with respective stakeholders
Release analytics of biosimilars, antibodies, current and future blockbusters in a GMP environment. Supervision of method transfers, stability studies, validation tasks. Handling and investigation of deviations and OOE/OOS results. Support for the laboratory coordinators.
In my Ph.D. I revealed interesting insights in the microbial degradation of polyisoprene latex on an enzymatic level. I focused on potential applications to employ generated oligo-isoprenoids as fine chemicals for special applications or use as a future biofuel.